Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betahistine intranasal - Altamira Therapeutics

Next Previous
Drug Profile

Betahistine intranasal - Altamira Therapeutics

Alternative Names: AM 125; AM-201 - Altamira Therapeutics; Betahistine dihydrochloride - Altamira Therapeutics

Latest Information Update: 19 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Melbourne
  • Developer Altamira Therapeutics; Otifex Therapeutics
  • Class Amines; Anti-inflammatories; Antidementias; Pyridines; Small molecules; Vestibular disorder therapies
  • Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No
  • Available For Licensing Yes - Vertigo

Highest Development Phases

  • Suspended Meniere's disease; Vertigo; Weight gain
  • Discontinued Otitis

Most Recent Events

  • 15 Jun 2023 US FDA approves IND application for Betahistine intranasal in Posterior canal benign paroxysmal positional vertigo (BPPV)
  • 15 Jun 2023 Altamira Therapeutics plans a phase II trial for Posterior canal benign paroxysmal positional vertigo (BPPV) in USA
  • 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in Vertigo in Unknown (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top